Atea Pharmaceuticals(AVIR)
BOSTON, MAPharmaceutical
Focus: Atea Pharmaceuticals is a Boston-based public biotech focused on nucleoside and nucleotide analogs targeting viral RNA polymerase, with a pipeline concentrated in hepatitis C and emerging viral indications. The company operates at mid-cap biotech scale with recent clinical momentum in late-stage hepatitis C programs.
Profile data last refreshed 13h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Atea Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Atea Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Atea Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
AT-587
Hepatitis EClinical Trials (1)
NCT07728487Study of AT-587 in Healthy Subjects
Phase 1Help build intelligence for Atea Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.